ERBB2 and neoplasm: In this study, we comprehensively characterize the genomic and proteomic landscape of HER2-negative breast cancer longitudinally, using mass spectrometry-based proteomics, bulk RNA microarray, single nucleus RNA sequencing (snRNA-seq), blood-tumor paired whole-exome sequencing (WES), histopathology, and in vitro validation.